How Chronic Pain Rewires the Brain's Reward System — And Why That Makes Cannabis and Opioid Misuse More Likely
Chronic pain and substance use disorders share a common neurobiological root: reduced dopamine signaling in the brain's reward pathway — creating a vulnerability where self-medication with opioids or cannabis can escalate into addiction.
Quick Facts
What This Study Found
Over 50 million Americans live with chronic pain, and many don't receive adequate treatment. This review tackles a question with enormous public health implications: why are chronic pain patients more likely to develop opioid and cannabis use disorders?
The answer centers on dopamine — the brain's reward and motivation chemical. Chronic pain suppresses dopamine signaling in the mesolimbic pathway (the brain's reward circuit), creating a state called hypodopaminergia. This reduced dopamine state does two things: it makes pain feel worse (because dopamine normally helps modulate pain perception) and it makes anything that boosts dopamine — including opioids and cannabis — feel especially rewarding.
Both opioids and cannabis temporarily restore dopamine signaling, relieving not just pain but the negative emotional state that accompanies chronic pain: the depression, anxiety, irritability, and loss of motivation. This dual relief — physical and emotional — is what drives self-medication and makes these substances so compelling for pain patients.
But the relief creates a trap. Repeated opioid or cannabis use further dysregulates dopamine signaling, deepening the hypodopaminergic state and increasing the drive to use. The brain adapts to the drug-boosted dopamine, and withdrawal makes the dopamine deficit even worse. This creates a cycle where the self-medication that initially provided relief gradually becomes part of the problem.
The review details the specific neurobiological mechanisms: how opioids modulate dopamine through mu-receptor activation in the ventral tegmental area, how cannabis modulates it through CB1 receptor effects on GABA and glutamate interneurons, and how chronic pain itself alters these circuits at a cellular level.
Key Numbers
Over 50 million Americans have chronic pain. High comorbidity between chronic pain and substance use disorders is well-documented. The mesolimbic dopamine pathway is central to both conditions. Opioids act through mu-receptors in the VTA; cannabis acts through CB1 receptors on GABA/glutamate interneurons. Chronic pain creates measurable hypodopaminergic transmission.
How They Did This
Narrative review synthesizing clinical evidence and neurobiological research on the link between chronic pain and opioid/cannabis use disorders. Covered: epidemiological data on comorbidity, dopaminergic mechanisms in pain and addiction, opioid and cannabinoid effects on mesolimbic dopamine signaling, and the neuroadaptations that link pain to substance misuse.
Why This Research Matters
Understanding why chronic pain leads to substance misuse isn't just academic — it should change how we treat both conditions. If the common root is hypodopaminergic signaling, then treating chronic pain more effectively might prevent substance misuse, and understanding the shared neurobiology might lead to treatments that address both conditions simultaneously rather than treating them as separate problems.
The Bigger Picture
This review provides the neuroscience backbone connecting several clusters in the RethinkTHC database. The dopamine-endocannabinoid interaction studies (RTHC-00072, RTHC-00073, RTHC-00075) described the basic science of how cannabinoids modulate dopamine. The tolerance and withdrawal studies (RTHC-00100, RTHC-00037) documented the brain adaptations that occur with chronic cannabis use. This review ties those mechanisms directly to chronic pain, explaining why the same biological system that cannabis acts on is dysregulated in pain patients — and why that creates both therapeutic opportunity and addiction risk.
What This Study Doesn't Tell Us
Narrative review, not systematic. While the dopaminergic hypothesis is compelling, chronic pain and addiction involve many neurotransmitter systems beyond dopamine (norepinephrine, serotonin, endogenous opioids, endocannabinoids). The causal direction isn't fully established — chronic pain may cause substance use disorders, substance use may worsen pain (opioid-induced hyperalgesia), or shared vulnerabilities may predispose to both. Most neurobiological evidence comes from animal models that don't fully capture the human experience of pain and addiction.
Questions This Raises
- ?Could dopamine-targeted treatments (like low-dose dopamine agonists) treat both chronic pain and associated substance misuse simultaneously?
- ?Would treating chronic pain more effectively with non-addictive approaches prevent the development of opioid and cannabis use disorders?
- ?Can we identify which chronic pain patients are at highest risk for developing substance use problems based on dopamine signaling markers?
Trust & Context
- Key Stat:
- Evidence Grade:
- Narrative review synthesizing clinical and preclinical evidence. The dopaminergic hypothesis is well-supported by both animal and human data, but the complete picture of pain-addiction comorbidity involves mechanisms beyond dopamine.
- Study Age:
- Published in 2024. The neuroscience of pain-addiction overlap is an active and rapidly evolving field.
- Original Title:
- Unveiling the link between chronic pain and misuse of opioids and cannabis.
- Published In:
- Journal of neural transmission (Vienna, Austria : 1996), 131(5), 563-580 (2024) — The Journal of Neural Transmission is a reputable journal focusing on neuroscience and neurobiology.
- Authors:
- Dagher, Merel, Alayoubi, Myra(3), Sigal, Gabriella H, Cahill, Catherine M
- Database ID:
- RTHC-05245
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- creativity-without-weed-quitting-artist-musician
- hobbies-after-quitting-weed
- identity-after-quitting-weed
- leaving-stoner-culture-identity
- medical-benefits-of-cannabis
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- quitting-weed-before-surgery
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- quitting-weed-weight-loss-gain
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- weed-withdrawal-tracker
- cannabis-recovery-community-support-group-compare
- cannabis-effects-and-experience-science
- why-more-creative-when-high-thc-divergent
- thc-and-weightlifting-muscle-growth-recovery
- thc-and-discipline-daily-use-willpower
- thc-creative-work-artists-musicians-writers
- cannabis-and-fibromyalgia-evidence-dosing
- cannabis-and-carpal-tunnel-nerve-pain
- cannabis-and-migraines-prevention-treatment
- cannabis-and-parkinsons-disease-tremor-sleep
- cannabis-recovery-devotional-30-days-scripture
- celebrate-recovery-vs-marijuana-anonymous
Cite This Study
https://rethinkthc.com/research/RTHC-05245APA
Dagher, Merel; Alayoubi, Myra; Sigal, Gabriella H; Cahill, Catherine M. (2024). Unveiling the link between chronic pain and misuse of opioids and cannabis.. Journal of neural transmission (Vienna, Austria : 1996), 131(5), 563-580. https://doi.org/10.1007/s00702-024-02765-3
MLA
Dagher, Merel, et al. "Unveiling the link between chronic pain and misuse of opioids and cannabis.." Journal of neural transmission (Vienna, 2024. https://doi.org/10.1007/s00702-024-02765-3
RethinkTHC
RethinkTHC Research Database. "Unveiling the link between chronic pain and misuse of opioid..." RTHC-05245. Retrieved from https://rethinkthc.com/research/dagher-2024-unveiling-the-link-between
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.